Rallybio Corporation is a biotechnology company focused on discovering and developing therapies for severe and rare diseases. Its lead product candidate, RLYB212, is a monoclonal anti-HPA-1a antibody in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia. The company also has other pipeline candidates in development and a collaboration with Exscientia for small molecule therapeutics.